Lehrstuhl für Innere Medizin I (Medizin 1)

Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing (2019) Schleier L, Wiendl M, Heidbreder K, Binder MT, Atreya R, Rath T, Becker E, et al. Journal article Semantic segmentation of non-linear multimodal images for disease grading of inflammatory bowel disease: A segnet-based application (2019) Pradhan P, Meyer T, Stallmach A, Waldner M, Schmitt M, Popp J, Bocklitz T, Vieth M Conference contribution Comparison of Hemospray® and Endoclot™ for the treatment of gastrointestinal bleeding (2019) Vitali F, Naegel A, Atreya R, Zopf S, Neufert C, Neurath M, Rath T, Siebler J Journal article Differentiation of malignant liver tumors by software-based perfusion quantification with dynamic contrast-enhanced ultrasound (DCEUS) (2019) Wildner D, Schellhaas B, Strack D, Görtz R, Pfeifer L, Fießler C, Neurath M, Strobel D Journal article Cap polyposis in children: case report and literature review (2019) Brunner M, Agaimy A, Atreya R, Grützmann R, Matzel KE Journal article Tumour Growth Rate (TGR) in Neuroendocrine Tumours (NETs): Changes Following Systemic Treatment; the GREPONET-2 Study (2019) Lamarca A, Ronot M, Moall S, Crona J, Opalinska M, Lopez C, Pezzutti D, et al. Conference contribution Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study (2019) Pavel ME, Dromain C, Thanh TXM, Houchard A Conference contribution Acoustic Radiation Force Impulse (ARFI) Elastography in Autoimmune and Cholestatic Liver Diseases (2019) Görtz R, Gassmann L, Strobel D, Wildner D, Schellhaas B, Neurath M, Pfeifer L Journal article Successful Long-term Treatment of Diversion Colitis with Topical Coconut Oil Application (2018) Zundler S, Dietz L, Matzel KE, Geppert CI, Becker E, Rath T, Neurath M, Atreya R Journal article, Letter Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx) (2018) Yao JC, Strosberg J, Fazio N, Pavel ME, Ruszniewski P, Bergsland E, Li D, et al. Conference contribution